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A Recurrent Mutation in PARK2
Is Associated with Familial Lung Cancer
Donghai Xiong,1,2 Yian Wang,1,2 Elena Kupert,2,3 Claire Simpson,4 Susan M. Pinney,5 Colette R. Gaba,6
Diptasri Mandal,7 Ann G. Schwartz,8 Ping Yang,9 Mariza de Andrade,9 Claudio Pikielny,10
Jinyoung Byun,10 Yafang Li,10 Dwight Stambolian,11 Margaret R. Spitz,12 Yanhong Liu,12
Christopher I. Amos,10 Joan E. Bailey-Wilson,4 Marshall Anderson,2,3 and Ming You1,2,*
PARK2, a gene associated with Parkinson disease, is a tumor suppressor in human malignancies. Here, we show that c.823C>T
(p.Arg275Trp), a germline mutation in PARK2, is present in a family with eight cases of lung cancer. The resulting amino acid change,
p.Arg275Trp, is located in the highly conserved RING finger 1 domain of PARK2, which encodes an E3 ubiquitin ligase. Upon further
analysis, the c.823C>T mutation was detected in three additional families affected by lung cancer. The effect size for PARK2
c.823C>T (odds ratio¼ 5.24) in white individuals was larger than those reported for variants from lung cancer genome-wide association
studies. These data implicate this PARK2 germline mutation as a genetic susceptibility factor for lung cancer. Our results provide a ratio-
nale for further investigations of this specificmutation and gene for evaluation of the possibility of developing targeted therapies against
lung cancer in individuals with PARK2 variants by compensating for the loss-of-function effect caused by the associated variation.Lung cancer (MIM 211980) is one of the most common
and deadly malignancies worldwide1 and originates from
complex gene-environment interactions. Prolonged expo-
sure to carcinogens found in tobacco smoke and other
environmental carcinogens that interact with various ge-
netic susceptibility factors contribute to lung cancer devel-
opment in humans. Although germline polymorphisms
have been associated with lung cancer susceptibility by
multiple genome-wide association studies (GWASs),2–5 lit-
tle is known about the existence of variants of large effect
in familial lung cancer.
PARK2 (MIM 602544; RefSeq accession number
NM_004562.2) is known to encode a RING-between-
RING-type E3 ubiquitin ligase. Although PARK2 alterations
are a causal factor of early-onset Parkinson disease (EOPD
[MIM 600116]), generally under a recessive mode of inher-
itance,6,7 PARK2 functions are also implicated in a wide
variety of biological processes regulating cell growth and
survival, such as the cell cycle, mitochondria homeosta-
sis, metabolism, xenophagy, protein turnover, and stress
response.8 Mutations in PARK2 abrogate the growth-sup-
pressive effects of wild-type PARK2 in different human
cancer cell lines, including lung cancer cell lines,9 making
PARK2 a candidate gene for involvement in lung can-
cer risk. In this study, we performed exome sequencing
in the probands of a specific lung-cancer-affected fam-
ily and identified an interesting PARK2 mutation. The
follow-up Sanger sequencing screen focusing on PARK2
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The Americlished that the recurrent germline mutation was signifi-
cantly associated with familial lung cancer and had a large
effect size.
Samples and clinical data used in this study were
collected by the following familial lung cancer recruitment
sites of the Genetic Epidemiology of Lung Cancer Con-
sortium (GELCC): University of Cincinnati, University
of Colorado, Karmanos Cancer Institute, Louisiana State
University Health Sciences Center, Mayo Clinic, Johns
Hopkins University, and University of Toledo. All
sites accrued participants according to institutional re-
view board (IRB)-approved protocols and obtained in-
formed consent from each participant. The Medical
College of Wisconsin Cancer Center also maintained an
IRB-approved protocol for analysis of the data. We first
studied a GELCC family in which eight members across
three generations developed lung cancer (family A; Tables
S1 and S2). Whole-exome sequencing (WES) was conduct-
ed on germline DNA for three lung cancer individuals
(III-1, III-4, and IV-18) in this family. The detailed WES
procedures can be seen in our previous publication.10 In
brief, whole-exome capture was carried out according to
the protocol for Agilent’s SureSelect Human All Exon Kit.
Then the captured fragments were sequenced on an Illu-
mina HiSeq 2000 with 100 bp paired-end reads. To achieve
high-level sensitivity and accuracy for variant detection,
we sequenced each sample at a mean depth of 1493. Short
sequence reads were aligned to a reference genome (UCSC
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Figure 1. Filtering Strategy in Family A
for the Three NSCLC Individuals Sub-
jected to Exome Sequencing
The filtering criteria are written on the left
side of the workflow. The number of vari-
ants that remained after each filtering
step is shown in the workflow.(BWA).11 The BWA assigned each alignment a mapping
quality score,11 which is the Phred-scaled probability that
the alignment is incorrect. We removed reads with low
mapping quality scores (<5) to reduce the false-positive
rate. The PCR duplicates were detected and removed by
the Picard program. We then performed local realignment
of the BWA-aligned reads by using the Genome Analysis
Toolkit (GATK).12 GATK was also used for base quality-
score recalibration and germline-variant calling. For
cross-validation, VarScan 213 was also used to call germline
variants according to the local-realignment results. Both
GATK and VarScan 2 were utilized to identify the shared
genetic variants between family members affected by
lung cancer. Default parameters in VarScan 2 were used.
The lists of shared single-nucleotide variants and indels
were then annotated with ANNOVAR.14
To identify the most significant germline mutations
associated with familial lung cancer risk in family A, we
applied the following filters for the variants called by our
exome sequencing pipeline: (1) the variants had to be pre-
sent in all three affected family members who were sub-
jected to exome sequencing; (2) variants present in the
SNP databases with a minor allele frequency (MAF) >
0.5% were excluded from further studies because they
are more likely to be functionally neutral polymorphisms
(the SNP databases that we used for filtering are dbSNP
build 137, 1000 Genomes, the NHLBI ESP6500 dataset,
and the 69-whole-genome dataset [variant calls and
allele-frequency information] from Complete Genomics);
(3) the variants had to belong to the category of missense
or nonsense mutations or indels, which would result in
altered or truncated protein products; (4) the variants
had to lie in the 6q23–q26 region, where we previously
detected significant linkage signals for familial lung cancer302 The American Journal of Human Genetics 96, 301–308, February 5, 2015in this family (denoted as family 102
in our previous publication) by
whole-genome scanning;15,16 (5) the
variants had to be predicted to be
functionally ‘‘not benign’’ or ‘‘not
tolerated’’ and related to cancer by
bioinformatics programs such as
PolyPhen-2, SIFT, and FATHMM. The
workflow of the variant-prioritiza-
tion steps is shown in Figure 1.
Completing the first four filtering
steps resulted in five candidate vari-
ants in the 6q23–q26 region (Table
1). Among them, the two UTRN
(MIM 128240; RefSeq NM_007124.2)variants were not associated with cancer as predicted by
FATHMM (scores > 0.75; Table 1), whereas the PACRG
(MIM 608427; RefSeq NM_152410.2) variant was pre-
dicted to be benign by PolyPhen-2 (score < 0.2), and the
NOX3 (MIM 607105; RefSeq NM_015718.2) variant was
predicted to be tolerated according to SIFT (score¼ 1; Table
1). In addition, the UTRN c.7794G>C (p.Gln2598His)
variant and the PACRG variant were not at the evolu-
tionary conservation site as predicted by GERPþþ (scores
< 2; Table 1). Only the PARK2 c.823C>T mutation, which
resulted in the substitution of arginine with tryptophan at
residue 275, stood out as the most critical germline variant
in family A.
We next performed Sanger sequencing for PARK2 exon
7 in family A subjects with available DNA. We designed
specific primers flanking exon 7 of PARK2. The primer
sequences were as follows: 50-CCAGTTCAACACAATT
CCTTCA-30 (forward) and 50-ACAACCCTCCAGGATTACA
GAA-30 (reverse). The standard PCR was conducted, and
the PCR amplicons were checked by gel electrophoresis
and then sent out to Eton Bioscience for Sanger
sequencing. The primers for PCR were also used for
sequencing reactions. DNA sequences were examined for
mutations with the software package Sequencher. An asso-
ciation between the c.823C>T (p.Arg275Trp) mutation
and non-small-cell lung cancer (NSCLC [MIM 211980])
was revealed. The c.823C>T (p.Arg275Trp) mutation was
detected in all the NSCLC subjects (III-1, III-4, III-7, III-
10, and IV-18) in family A (Figures 2 and 3). One person
(IV-12) who carried the c.823C>T (p.Arg275Trp) germline
mutation had childhood leukemia and died at a relatively
young age (44 years old) prior to entering the age range for
substantial risk of lung cancer. One small cell lung cancer
(SCLC [MIM 182280]) subject (V-1) had wild-type alleles
Table 1. Characteristics of the Five Candidate Variants in 6q23–q26 for Familial Lung Cancer in Family A
Gene
Genomic
Positiona
Genomic
Mutation Exon
Protein
Alteration
Predicted Effect of Missense Mutation
dbSNP137
ESP
MAFfPolyPhen-2b SIFTc FATHMMd GERPþþe
PARK2 chr6:
162,206,852
c.823C>T 7 p.Arg275Trp probably
damaging (1.00)
deleterious
(0.00)
potentially
associated
with cancer
(3.47)
4.87 rs34424986 0.002
UTRN chr6:
144,808,805
c.3944A>C 28 p.Asn1315Thr probably
damaging (0.992)
deleterious
(0.00)
not associated
with cancer (1.78)
3.95 NA NA
UTRN chr6:
145,021,364
c.7794G>C 52 p.Gln2598His probably
damaging (0.99)
deleterious
(0.00)
not associated
with cancer (1.58)
2.12 NA NA
NOX3 chr6:
155,776,042
c.158G>T 3 p.Trp53Leu probably
damaging (0.996)
tolerated
(1.00)
potentially
associated with
cancer (3.48)
5.91 rs200865731 NA
PACRG chr6:
163,149,345
c.78A>C 2 p.Gln26His benign (0.19) deleterious
(0.01)
not associated
with cancer (0.77)
1.18 rs80012280 NA
Abbreviations are as follows: ESP, NHLBI Exome Sequencing Project; and NA, not available.
aGenomic positions are given according to the UCSC Genome Browser hg19 reference assembly.
bPolyPhen-2 scores 0.85–1 are interpreted as probably damaging, scores 0.2–0.85 are possibly damaging, and scores 0–0.2 are benign.
cSIFT scores range from 0 to 1. The amino acid substitution is predicted to be damaging if the score is %0.05 and tolerated if the score is >0.05.
dPredictions with FATHMM scores less than 0.75 indicate that the mutation is potentially associated with cancer; otherwise, the mutation is not associated with
cancer.
eAn indication of evolutionary conservation is made if a given site shows a GERPþþ score > 2.
fMAFs are according to the NHLBI GO Exome Sequencing Project (ESP6500SI-V2 release) Exome Variant Server v.0.0.21 (August 2013).at this locus, suggesting a possible lung-cancer-subtype
specificity for the c.823C>T (p.Arg275Trp) allele. No bio-
logical specimens were available for the other two SCLC
subjects (IV-7 and IV-9). Among the 25 family members
who did not have lung cancer at the time of last contact,
six had the c.823C>T (p.Arg275Trp) mutation, and 19
had wild-type alleles at this locus (family A in Figure 3).
Next, we conducted Sanger sequencing screening of
exon 7 of PARK2 in an additional 111 unrelated familial
lung cancer subjects and identified two additional families
carrying the c.823C>T (p.Arg275Trp) mutation. There
were no reported SCLC subjects in these families. As shown
in Figure 3 and Figure S1, the mutation was detected in the
two lung cancer subjects (III-6 and III-7) in family B and
in two lung cancer subjects (II-1 and II-3) in family C. It
should be noted that individuals I-1 and II-2 in family C
had wild-type alleles at this locus. However, I-1 was
affected by both lung cancer and prostate cancer, so it
is likely that he and his daughter (II-2) carried a
different risk allele for lung cancer than the c.823C>T
(p.Arg275Trp) allele in the other two subjects in this bilin-
eal family. We had blood DNA available for a sister and a
nephew of I-1 (both unaffected by lung cancer), and
sequencing showed that they also had wild-type alleles at
this locus, which further strengthened our argument that
the father’s side had causes of lung cancer other than
the c.823C>T (p.Arg275Trp) mutation. The c.823C>T
(p.Arg275Trp) variant was also found in the proband of a
biospecimen-limited familial-lung-cancer-affected family
(family D), for which only the proband (II-2), who had
lung adenocarcinoma, was recruited (Figure 3, Figure S1).
This individual was sequenced by an exome sequencing
project that screened 55 independent familial lung can-The Americcer subjects. These results support PARK2 c.823C > T
(p.Arg275Trp) as a lung cancer risk variant. In addition,
combining the smoking-status information with themuta-
tion data for the three multiple-case families (A–C in Table
S1) showed that the frequency of c.823C>T (p.Arg275Trp)
did not vary significantly according to the smoking status
of themembers in these families (themutation was present
in 8 of 21 smokers [frequency ¼ 0.19] and 10 of 30 people
who never smoked [frequency¼ 0.17]), suggesting that the
mutation might act independently of smoking status in
increasing lung cancer susceptibility.
The PARK2 c.823C>T (p.Arg275Trp) mutation is
extremely rare in the general population; according to the
ESP6500 dataset, the MAF of the mutant T allele in all
ethnic groups combined is 0.002 (Table 1).We tested the as-
sociation between this mutation and familial lung cancer.
Because the lung-cancer-affected families we studied are
all of white ethnicity, in order to exclude the potential con-
founding effect of ethnicity in the association analysis, we
compared the frequencies between our family lung cancer
cases consisting of white individuals and the control
groups restricted to white ethnicity. First, ESP6500 data
showed that the MAF of the c.823C>T (p.Arg275Trp)
mutant A allele (the sequence read is the A allele on
the complementary strand of the real PARK2 mutant T
allele) in 4,300 white individuals is 0.0029 (25/8,600).
In addition, an Affymetrix genotyping study in 2,134
healthy control individuals showed with the latest high-
throughput Axiom Biobank Arrays that the MAF of the
c.823C>T (p.Arg275Trp) mutant allele in 544 white indi-
viduals is 0 (0/1,088, see Affymetrix in theWeb Resources).
We also estimated the frequency by using our own exome-
chip data of 2,642 unrelated subjects (1,562 whitean Journal of Human Genetics 96, 301–308, February 5, 2015 303
Figure 2. Sanger Sequencing Chromato-
grams of the PARK2Mutation and the Plot
of the Resulting Amino Acid Change in
the PARK2 Domain
The top panel shows the sequencing chro-
matograms of the PARK2 germline muta-
tion c.823C>T for the three probands in
family A, and the bottom panel presents
the schematic plot of PARK2 domains
and the amino acid change (p.Arg275Trp)
resulting from c.823C>T. Chromatograms
of both forward and reverse sequences are
given, and the complementary-strand al-
leles (G>A) are shown. The solid red arrow-
head shows the location of the resulting
amino acid change in PARK2.individuals and 1,080 African Americans) who were ascer-
tained in three eye disease studies and were not known to
have lung cancer. Out of the total 3,124 alleles of the
1,562 white individuals, five copies of the c.823C>T
(p.Arg275Trp) mutant allele were found, yielding a MAF
of 0.0016 (5/3,124). In addition, no copies of the mutant
allele were observed in our other exome-chip data from
98 unrelated white probands from 49 independent pedi-
grees ascertained for a strong history of myopia (MIM
614292) in the Myopia Family Study, making the MAF
0 (0/196). The frequency of the c.823C>T (p.Arg275Trp)
mutation in our cohort of independent familial lung cancer
subjects of white ethnicity is 0.012 (4 / [1123 2 þ 553 2])
and is significantly higher than the combined control
white populations’ frequency of 0.0023 (30/13,008,
combining 25/8,600 from ESP6500, 0/1,088 from the Affy-
metrix study, 5/3,124 from the eye disease study, and 0/196
from theMyopia Family Study; p¼ 0.009; odds ratio [OR]¼
5.24; 95% confidence interval ¼ 1.33–15.00; two-tailed
Fisher’s exact test). The effect size of the c.823C>T
(p.Arg275Trp) mutation is larger than those reported for
variants from a lung cancer GWAS.17 These results suggest
that carrying this PARK2mutation is associated with signif-
icantly higher odds of developing familial lung cancer in
white individuals. We also queried the Exome Aggregation
Consortium (ExAC) database, which contains allele-fre-
quency data generated by a wide variety of large-scale pro-
jects that sequenced a total of 61,486 exomes. It was
found that in the European (non-Finnish) population,
the c.823C>T (p.Arg275Trp) variant had a MAF of 0.0031
in 209/66,834 chromosomes. This is a little bigger than
the frequency in our control sample (MAF¼ 0.0023). How-
ever, the ExAC dataset contains data from thousands of
exomes (contributed by TCGA [TheCancer Genome Atlas])
from cancer-affected individuals; therefore, the estimated
frequency of the c.823C>T (p.Arg275Trp) mutation ac-
cording to the ExAC dataset is biased and not ideal for com-
parison with our lung cancer subjects.
A recent study showed that PARK2 acts as a master regu-
lator of the stability of G1/S cyclins and functions as the304 The American Journal of Human Genetics 96, 301–308, Februarytumor suppressor mediating the coordination of different
classes of cyclins.18 Such coordination is fundamentally
important for cell-cycle regulation and tumor suppres-
sion, and loss-of-function mutations in PARK2 have
been associated with different types of human cancers.18
The p.Arg275Trp substitution is located in the highly
conserved and functionally important RING finger 1
domain (amino acids 238–293; Figure 2) of PARK2.9 Previ-
ous studies have shown that it causes subcellular mislocal-
ization of PARK2 and aggresome formation in normal cell
lines, suggesting that it manifests as a loss-of-function
alteration.19,20 It is located at the same amino acid residue
as that affected by a somatic mutation implicated in
lung cancer, i.e., c.824G>A (p.Arg275Gln).9 The latter
has been shown to significantly decrease PARK2’s E3 ligase
activity, compromise its ability to ubiquitinate cyclin E,
result in mitotic instability, and eliminate the tumor-sup-
pressive effect of the wild-type PARK2 in multiple lung
cancer cell lines.9 This was confirmed by an indepen-
dent study, which further showed that the inactivating
c.824G>A (p.Arg275Gln) mutation resulted in the accu-
mulation of cyclin D and cyclin E and subsequent highly
accelerated cell-cycle progression leading to tumorigen-
esis.18,21 On the other hand, a logical explanation for the
dysfunction of the aggregation-prone PARK2missense mu-
tation (c.823C>T [p.Arg275Trp]) is based on the impair-
ment of the ubiquitin-proteasome system by protein
aggregation, either by exhaustion of one or more factors
(such as chaperones) required for normal function or by
a ‘‘clogged’’ proteasome.22 Aggregation induced by PARK2
c.823C>T (p.Arg275Trp), even in cells with heterozygous
mutation status, could eventually result in severe proteaso-
mal dysfunction,19,20,23,24 which could also cause the accu-
mulation of excessive cyclin D and cyclin E, as c.824G>A
(p.Arg275Gln) did, and finally lead to the deregulated
G1/S-phase cyclin turnover and ultimately cancer.18,21 In
addition, cBioPortal for Cancer Genomics25 shows that
PARK2 somatic mutations are found in 2.7%–3.5% of
lung adenocarcinoma, 5.6% of lung squamous cell carci-
noma, and 4.8% of SCLC (Figure S2). Interestingly, the5, 2015
Figure 3. The PARK2 c.823C>T (p.Arg275Trp) Mutation in Four Lung-Cancer-Affected Families
Basic annotations are as follows: the black filled symbols indicate lung-cancer-affected individuals; an oblique line shows deceased fam-
ily members; the numbers ending with ‘‘ y’’ under each symbol indicate the age at diagnosis (affected individuals) or last contact (control
individuals); ‘‘Smk’’ means a current or former smoker; ‘‘Nev’’ indicates someone who never smoked; ‘‘c.823C>T’’ indicates a subject
with the heterozygous c.823C>T (p.Arg275Trp) mutation; and ‘‘WT’’ indicates a subject with wild-type alleles at this locus. In family
A, five lung-cancer-affected subjects (III-1, III-4, III-7, III-10, and IV-18 [black filled symbols]; age at onset ranging from 38 to 69 years)
without SCLC had the c.823C>T (p.Arg275Trp) mutation. WES was performed for affected individuals III-1, III-4, and IV-18. Subject IV-
12 (symbol with vertical black bar in the center) had leukemia. Three individuals (IV-7, IV-9, and V-1 [half-black symbols]) were affected
by SCLC. Six unaffected individuals (age at exam ranging from 30 to 55 years) had the c.823C>T (p.Arg275Trp) mutation, and 19 un-
affected (age at exam ranging from 26 to 75 years) had wild-type alleles at this locus. In family B, two NSCLC-affected individuals (III-6
and III-7) had the c.823C>T (p.Arg275Trp) mutation. Three unaffected individuals (age at exam ranging from 25 to 49 years) had this
mutation, and 13 unaffected (age at exam ranging from 30 to 69 years) hadwild-type alleles at this locus. Individual III-4 (symbol with an
inner black circle) had both lung cancer and melanoma, but her DNA sample was unavailable for genetic testing. In family C, two
NSCLC-affected individuals (II-1 and II-3; ages at onset of 57 and 59 years, respectively) had the c.823C>T (p.Arg275Trp) mutation. In-
dividual I-1 (symbol with an inner black circle) had both lung cancer and prostate cancer, and I-2 (symbol with an inner black circle) had
uterine cancer and potentially had lung cancer (this is unverified, and this individual has been out of contact since 2002). In family D,
individual II-2 had the mutation (age at onset was 47 years) and had lung adenocarcinoma. Individual I-2 (symbol with an inner black
circle) had both lung adenocarcinoma and leukemia.list of PARK2 somatic mutations identified by TCGA
includes a protein-coding mutation that affects amino
acid residue 275 and results in a substitution of arginine
with proline (p.Arg275Pro, highlighted in red in Table
S3), again indicating the involvement of this locus in
lung tumorigenesis. Taken together, all the evidence sug-The Americgests that residue Arg275 of PARK2 is critical to both
lung cancer susceptibility and tumorigenesis.
We designed 12 pairs of PCR primers (Table S4) for the
amplification and Sanger sequencing of all 12 exons of
PARK2 in the 112 unrelated subjects with familial lung
cancer, which revealed four additional PARK2 missensean Journal of Human Genetics 96, 301–308, February 5, 2015 305
mutations in the lung-cancer-affected families in whom
the c.823C>T (p.Arg275Trp) variant was not present (Table
S5). These variants cause PARK2 alterations p.Arg256Cys,
p.Asp280Asn, p.Ser223Leu, and p.Arg402Cys, which are
also predicted in silico by bioinformatics tools to be
damaging and potentially associated with cancer (Table
S5). Three of the variants (c.766C>T [p.Arg256Cys],
c.838G>A [p.Asp280Asn], and c.1204C>T [p.Arg402Cys])
are rare mutations already recorded in public databases,
whereas the c.668C>T (p.Ser223Leu) variant is the de
novo mutation we report here (Table S5). However, they
are not recurring mutations, as c.823C>T (p.Arg275Trp)
was in our dataset, and it is not feasible to conduct appro-
priate cosegregation analysis in these families because each
family has only one affected proband with an available
DNA sample. We present the three pedigrees with the
corresponding genotype information for the c.766C>T
(p.Arg256Cys), c.838G>A (p.Asp280Asn), and c.668C>T
(p.Ser223Leu) mutations in Figure S3. The pedigree infor-
mation for the proband bearing c.1204C>T (p.Arg402Cys)
was not available, although we archived the DNA sample
from this proband.
The families in our collection have not reported a history
of Parkinson disease (PD [MIM 168600]), excluding the
possible confounding effect of PD on our study. A literature
search revealed an inverse association between PD and
spontaneous lung cancer. Such association was largely
from strong epidemiologic evidence suggesting that the
most prominent lung cancer risk factor, smoking, is protec-
tive against PD.26–30 Yet, studies have also shown that co-
horts of individuals with PD do reveal a significant increase
in the risk of malignancies such as melanoma and brain
and breast cancers.30,31 Because the PARK2 mutations
were generally not analyzed in the previous epidemiology
studies of PD, the association status of PARK2 with lung
cancer risks in PD-affected individuals is unknown. How-
ever, lung cancer and EOPD have different ranges of age
of onset. EOPD occurs within the age range of 21–40
years,32 whereas only about 2.3% of lung cancer occurs
before age 44 (see the corresponding link in the Web Re-
sources). In our studied lung-cancer-affected families,
only one individual (III-4 in family A) was diagnosed
with NSCLC before age 40 (onset age of 38 years), whereas
all other subjects were in the onset age range of 47–84
(mean onset age of 62 years). So, individuals with the
PARK2 variant and EOPD might not reach the onset age
for developing lung cancer, which could explain the
possible situation that no increased risk of lung cancer
has been found for them yet.
RGS17 (MIM 607191; RefSeq NM_012419.4) is one po-
tential candidate gene underlying the 6q linkage to famil-
ial lung cancer, as we reported before.16 However, using
exome sequencing, we did not find any functional
RGS17 variants that were shared among lung cancer sub-
jects in family A. In this family, we only detected one syn-
onymous RGS17 mutation (c.54T>G), which did not lead
to an amino acid change (p.¼). Our previous studies306 The American Journal of Human Genetics 96, 301–308, Februaryalready showed that the linkage to lung cancer in family
A spanned a broad genomic region of 6q23–q26, including
6q26, which harbors PARK2.15,16 Our systematic variant-
prioritization steps for family A, as shown in Figure 1, guar-
anteed that the PARK2 c.823C>T (p.Arg275Trp) variant
was the best candidate in the region 6q23–q26. Therefore,
this functional variant in PARK2 is more likely than other
variants to account for the lung cancer susceptibility in
family A.
Through WES of individuals from a multiple-case lung-
cancer-affected family and the follow-up Sanger seq-
uencing screen of additional lung-cancer-affected families,
we identified a recurrent loss-of-function germline muta-
tion, i.e., c.823C>T (p.Arg275Trp), in PARK2 in four
lung-cancer-affected families. Although common variants
(MAF > 1%) associated with lung cancer have been de-
tected by GWASs, a considerable proportion of ‘‘missing
heritability’’ is still unexplained and might be due to
undiscovered rare sequence variants. In a recent study,
two rare mutations (MAF < 0.5%) causing alterations in
proteins encoded by BRCA2 (MIM 600185) and CHEK2
(MIM 604373) were revealed to have a large effect on
the risk of spontaneous squamous lung cancer: BRCA2
c.9976A>T (p.Lys3326*) (rs11571833; OR ¼ 2.47; p ¼
4.74 3 1020; 95% confidence interval ¼ 2.04–3.00) and
CHEK2 c.470T>C (p.Ile157Thr) (rs17879961; OR ¼ 0.38;
p ¼ 1.27 3 1013; 95% confidence interval ¼ 0.29–
0.49).17 The effect size of PARK2 c.823C>T (p.Arg275Trp)
(OR¼ 5.24) on familial lung cancer is larger than the effect
sizes of the BRCA2 and CHEK2 rare variants on sponta-
neous lung cancer. Our finding is similar to that of an
exome sequencing study that revealed the large effect of
MITF (MIM 156845) c.1075G>A (p.Glu318Lys) on familial
melanoma (OR ¼ 8.37; 95% confidence interval ¼ 2.58–
23.80).33 Our data warrant further research into the delete-
rious PARK2mutations or other PARK2 genetic variants for
exploration of the potential feasibility of developing tar-
geted therapies against lung cancer in individuals with
PARK2 variants by compensating for the loss-of-function
effect caused by the corresponding variation.Supplemental Data
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